MALT Lymphoma

13 clinical trials · Condition

Record	Firm	Date
PSB202 in Patients With Previously Treated-, Relapsed-, Indolent B-Cell Malignancies (NCT05003141)	Qilu Puget Sound Biotherapeutics (dba Sound Biologics)	2021-11-15
Endomicroscopy and Gastric MALT-lymphoma (NCT01583699)	Medical University of Vienna	2012-04-01
Trial of Lenalidomide in Patients With Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) Type (NCT00923663)	Medical University of Vienna	2009-07-01
Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma (NCT01015248)	Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea	2009-05-01
Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas (NCT00783367)	Abramson Cancer Center at Penn Medicine	2008-07-01
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients (NCT00373646)	Medical University of Vienna	2006-06-01
Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma (NCT00117156)	Dana-Farber Cancer Institute	2003-12-01
Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma (NCT00201422)	National Health Research Institutes, Taiwan	1996-06-01
Velcade in MALT Lymphoma Patients (NCT00373906)	Medical University of Vienna

Every clearance here is in the API, with alerts when new ones post.